Landfair Capital Raises Its First Fund, Landfair European Dislocated Opportunities Fund

Stallergenes Greer Announces Positive Phase 3 Results for Peanut Allergy Treatment

Allergy Partners Announces Acquisition of Charleston Allergy and Asthma

Allergy Partners Appoints Chris Kane as Chief Executive Officer

Stallergenes Greer Announces Global Agreement with Nestle Regarding the Peanut Oral Immunotherapy Treatment Palforzia®

Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings

GPC's Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer

Corium and Gurnet Point Capital Announce Manufacturing Business Acquisition and a $100 Million Neuroscience Therapeutics Investment by Webster Equity Partners

Capital Four's Private Debt III Fund closes above target and at hard cap of €1.5 billion

Allergy Partners and Trio Health Partner to Form National Allergy and Asthma Patient Registry

Allergy Partners joins Consortium of Independent Immunology Clinics (CIIC)

Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital

Forestay Capital Leads Manta's $35m Series B

Peter Sanborn Joins Arbor Ventures as General Partner; will lead Arbor B-FLEXION Growth Fund

Boston Pharmaceuticals Appoints Dr. Sophie Kornowski as Chair of its Board of Directors and Acting Chief Executive

B-FLEXION Sells Affidea Group to GBL

Corium receives FDA approval of ADLARITY for patients with Alzheimer's Disease

Forestay Leads Series B round in Convelio

Forestay Invests Again in Zenjob

Forestay investment, Scandit, goes Unicorn with Series D

Forestay portfolio investment, BlueBotics, acquired by ZAPI

From Waypoint to B-FLEXION

Waypoint Capital Acquires Majority Stake in Allergy Partners

Boston Pharmaceuticals Signs Pioneering Out-License Agreement With GSK

Waypoint Capital Appoints Elias Zerhouni to Board of Directors

GPC's Portfolio Investment, Before Brands, Secures Backing from Nestle Health Science

Forestay Capital Invests in Kandou, a global leader in connectivity IP and chip solutions

vCita Secures $15M Growth Funding Round Led by Forestay Capital

Forestay Capital invests in icometrix, the brain imaging AI leader

Gurnet Point Capital Completes Acquisition of Corium International, Inc.

Forestay Capital Invests in Swiss Navigation Company, BlueBotics

Forestay Capital Invests in Cloud Storage Company, Wasabi

Waypoint Appoints New Group General Counsel

Change of Esaote’s ownership has been completed

Affidea Group Appoints New Chief Executive Officer

Change of ownership of Esaote

Waypoint takes part in $17m Series B Funding Round in Fornova

Waypoint's Chairman, Ernesto Bertarelli, receives the Gallatin Award

Gurnet Point L.P. enters into agreement to acquire Innocoll Holdings plc

Gurnet Point Capital Leads Series B Financing of Before Brands

Gurnet Point Invests $92M in Primary Care Innovator Crossover Health

Gurnet Point Capital Invests in BEFORE Brands, a science-based consumer products company dedicated to bringing innovative, proprietary nutritional products directly to families

Gurnet Point Capital invests in Pronutria Biosciences, with Christopher Viehbacher joining the Board

Gurnet Point Capital launches new drug development company, Boston Pharmaceuticals

Crosstree win planning approval for Mayfair project

Waypoint appoints Chris Viehbacher to lead healthcare investment strategy

Waypoint Capital will purchase Euromedic International